Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:03:28 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:RDHL from 2023-05-04 to 2024-05-03 - 28 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 07:00U:RDHLNews ReleaseRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
2024-04-08 09:23U:RDHLNews ReleaseRedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
2024-04-02 07:00U:RDHLNews ReleaseRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
2024-03-11 07:00U:RDHLNews ReleaseRedHill Announces New USPTO Patent Covering Talicia(TM) Through 2034
2024-03-05 07:00U:RDHLNews ReleaseRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
2024-02-20 07:00U:RDHLNews ReleaseRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
2024-01-26 12:46U:RDHLNews ReleaseRedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
2024-01-25 09:05U:RDHLNews ReleaseRedHill Biopharma Announces $8 Million Registered Direct Offering
2024-01-25 06:00U:RDHLNews ReleaseRedHill Announces New USPTO Patent Grant for Talicia ‚ ® for H. pylori Treatment Through 2042
2023-12-20 08:45U:RDHLNews ReleaseRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
2023-12-12 07:00U:RDHLNews ReleaseRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-12-04 07:00U:RDHLNews ReleaseRedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
2023-11-27 07:00U:RDHLNews ReleaseRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia ‚ ® with IP Protection Running to 2034
2023-11-14 08:00U:RDHLNews ReleaseRedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
2023-10-03 07:00U:RDHLNews ReleaseRedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
2023-09-22 16:15U:RDHLNews ReleaseRedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
2023-09-18 07:00U:RDHLNews ReleaseRedHill Announces FDA sNDA Approval for Talicia ‚ ®
2023-09-05 07:00U:RDHLNews ReleaseRedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA ‚ ®)
2023-08-17 07:00U:RDHLNews ReleaseRedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
2023-08-01 07:00U:RDHLNews ReleaseRedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
2023-07-31 07:00U:RDHLNews ReleaseRedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
2023-07-25 15:58U:RDHLNews ReleaseRedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
2023-07-21 09:33U:RDHLNews ReleaseRedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
2023-07-21 07:00U:RDHLNews ReleaseRedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
2023-06-12 08:00U:RDHLNews ReleaseRedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
2023-05-22 07:00U:RDHLNews ReleaseRedHill Provides R&D Update
2023-05-15 18:17U:RDHLNews ReleaseRedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
2023-05-09 07:00U:RDHLNews ReleaseRedHill Publishes New Talicia ‚ ® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week